title: Drug interactions.
abstract: Drugs for allergy are often taken in combination with other drugs, either to treat allergy or other conditions. In common with many pharmaceuticals, most such drugs are subject to metabolism by P450 enzymes and to transmembrane transport. This gives rise to considerable potential for drug-drug interactions, to which must be added consideration of drug-diet interactions. The potential for metabolism-based drug interactions is increasingly being taken into account during drug development, using a variety of in silico and in vitro approaches. Prediction of transporter-based interactions is not as advanced. The clinical importance of a drug interaction will depend upon a number of factors, and it is important to address concerns quantitatively, taking into account the therapeutic index of the compound.
authors: Department of Experimental Medicine and Toxicology, Division of Medicine, Imperial College London, Hammersmith Campus, London. a.boobis@imperial.ac.uk
authors: Alan
authors: A
authors: Boobis
authors: Jean-Baptiste
authors: JB
authors: Watelet
authors: Rhys
authors: R
authors: Whomsley
authors: Margherita Strolin
authors: MS
authors: Benedetti
authors: Pascal
authors: P
authors: Demoly
authors: Keith
authors: K
authors: Tipton
mesh_terms: D000818:Animals; D018926:Anti-Allergic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D002352:Carrier Proteins / Q000378:metabolism; D065607:Cytochrome P-450 Enzyme Inhibitors; D003577:Cytochrome P-450 Enzyme System / Q000096:biosynthesis; D004032:Diet; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D018565:Food-Drug Interactions; D006801:Humans; D008954:Models, Biological
chemical_list: D018926:Anti-Allergic Agents; D002352:Carrier Proteins; D065607:Cytochrome P-450 Enzyme Inhibitors; D003577:Cytochrome P-450 Enzyme System